Xin Lang Cai Jing·2025-11-12 02:12Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Innovation Drug Selected Index, which rose by 3.17%, with significant gains from individual stocks such as BeiGene, which increased by 7.29% [3] - The Hong Kong Innovation Drug Selected ETF (520690) also saw an increase of 2.90%, closing at 0.92 yuan, and has shown a cumulative rise of 0.56% over the past two weeks, ranking in the top half among comparable funds [3] - BeiGene, as a leading global innovative drug company, reported sales of its core product, Zebrutinib, exceeding $1 billion in Q3 2025, reflecting over 50% year-on-year growth across major markets including the US, Europe, and China [3] Group 2 - The report from CICC indicates a clear trend of innovation going global, with the pharmaceutical sector leading the way, supported by domestic engineering talent, abundant clinical resources, and favorable policies [4] - The Hong Kong Innovation Drug Selected ETF experienced a significant scale increase of 485.88 million yuan over the past week, indicating strong market interest [4] - The top ten weighted stocks in the Hang Seng Hong Kong Stock Connect Innovation Drug Selected Index account for 72.15% of the index, with major companies including BeiGene and China Biologic Products [4]